SHAO

JLCPCB hosts Strange Parts for Factory Visit and Unveils Secrets of Flexible PCB Manufacturing

Retrieved on: 
Friday, September 8, 2023
Polychlorinated biphenyl, SHAO, FPC, Flexible electronics, Life, Flexible, PCB, Printed circuit board

SHAO GUAN, China, Sept. 8, 2023 /PRNewswire-PRWeb/ -- In a visit aimed at unveiling the secrets of flexible PCB manufacturing, JLCPCB hosts the popular YouTube channel Strange Parts for a factory visit and tour of its latest technology manufacturing. The below video introduces each step of the manufacturing process of Flexible PCB. From material preparation, circuit printing, component placement, soldering, testing, and stiffener attachment, witnessing the complete production process of FPC from raw material to finished assembled circuit boards.

Key Points: 
  • Leading global electronics manufacturing service provider, JLCPCB hosts Strange Parts for an insightful factory visit, thoroughly exploring the production process of Flexible PCB and offering viewers unprecedented manufacturing insights.
  • SHAO GUAN, China, Sept. 8, 2023 /PRNewswire-PRWeb/ -- In a visit aimed at unveiling the secrets of flexible PCB manufacturing, JLCPCB hosts the popular YouTube channel Strange Parts for a factory visit and tour of its latest technology manufacturing.
  • In addition to manufacturing flexible PCB, JLCPCB is also supported for flexible PCB assembly.
  • This offer empowers innovators to explore the possibilities of flexible PCB and other PCB manufacturing options without financial constraints.

Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma

Retrieved on: 
Thursday, September 7, 2023
US Foods, Intensity, Vinblastine, Marketing, Survival, STS, Cisplatin, Trial of the century, SHAO, ASCO, Sarcoma, Orphan drug, Johns Hopkins University, Patient, Cancer, FDA, Therapy, Food, Pharmaceutical industry

"The designation of cisplatin, vinblastine and our diffusion enhancer, SHAO for orphan status for STS is quite important," said Lewis H. Bender President and CEO.

Key Points: 
  • "The designation of cisplatin, vinblastine and our diffusion enhancer, SHAO for orphan status for STS is quite important," said Lewis H. Bender President and CEO.
  • An FDA condition to obtain orphan drug designation was for the Company to provide a scientific rationale in its application with sufficient data to establish a medically plausible basis for expecting the drug to be effective in STS.
  • The Company submitted clinical data including immune activation results in sarcoma patients.
  • Data also reported at ASCO showed that INT230-6 when delivered locally led to a systemic immune response in several sarcoma subtypes that are considered to be non-immunogenic cancers.

Intensity Therapeutics' INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas

Retrieved on: 
Saturday, June 3, 2023
Neoplasm, Intensity, Response evaluation criteria in solid tumors, DCR, Survival, Clinical trial, RECIST, Cancer, Royal Marsden Hospital, SHAO, ASCO, Sarcoma, Publication, American Society of Clinical Oncology, Johns Hopkins University, The Royal Marsden NHS Foundation Trust, Patient, TTB, Ipilimumab, Subbiah, Tumor necrosis factor, Scientific Reports, IPI, BMS, Cisplatin, MOS, Pharmacology, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, SD, Food, Pharmaceutical industry, Vinblastine

WESTPORT, Conn., June 3, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral (IT) cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that data from its ongoing phase 1/2 clinical trial demonstrating the efficacy and tolerability of INT230-6, either as monotherapy or in combination with ipilimumab in patients with relapsed, refractory and metastatic sarcomas, will be presented this afternoon at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago and virtually from June 2-6, 2023.

Key Points: 
  • Abstract Title: Intratumoral INT230-6 (Cisplatin, Vinblastine, SHAO) alone or with ipilimumab (IPI) prolonged survival with favorable safety in adults with refractory sarcomas [Intensity IT-01; BMS#CA184-592].
  • Sarcoma remains a very challenging cancer to treat and has historically proven resistant to checkpoint blockade.
  • Novel approaches are needed for this patient population, and Intensity's data indicate that sarcoma is an attractive target for intratumoral injection.
  • For the combination arm, one subject had yet to reach the first timepoint for SD at the time of data cut-off.

Intensity Therapeutics' Reports Up to 100% Tumor Necrosis After One Dose of Lead Asset, INT230-6 in Phase 2 INVINCIBLE Neoadjuvant Breast Cancer Study at the San Antonio Breast Cancer Symposium (SABCS)

Retrieved on: 
Thursday, December 8, 2022
Therapy, Malignancy, Breast cancer, Vinblastine, National Cancer Institute, Injection, Ipilimumab, Neoplasm, NCT, Intensity, Woman, Data analysis, CD4, Mastectomy, Cooperative research and development agreement, Necrosis, Risk, Development, Bristol Myers Squibb, The Ottawa Hospital, Oncology nursing, Pain, Cisplatin, Ottawa Hospital Research Institute, Clinical trial, Merck & Co., University, T helper cell, Immunosuppression, Pembrolizumab, NCI, Diffusion, NK, Merck Sharp & Dohme Federal Credit Union, Diagnosis, OHRI, Cancer, Annual general meeting, Merck, Breast, Tumor necrosis factor, Immune system, Surgeon, Ontario Institute for Cancer Research, Poster, Patient, SHAO, CRADA, Medicine, Cell death, WOO, Publication, Pharmaceutical industry, Medical imaging, Vaccine

WESTPORT, Conn., Dec. 8, 2022 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary, first-in-class immune-based cancer therapies designed to kill tumors and increase immune system recognition of cancers, today presented new data from the INVINCIBLE study in a live Spotlight Session Poster Presentation at the San Antonio Breast Cancer Symposium (SABCS) Annual Meeting being held at the Henry B. Gonzalez Convention Center, San Antonio, TX, from December 6-10, 2022.

Key Points: 
  • INT230-6 demonstrated the ability to cause up to 100% necrosis of presurgical breast cancer tumors in the window period from diagnosis to surgery.
  • Adverse events were mostly grade 1 with expected pain at the breast injection site; there were very few systemic adverse effects.
  • There is a waiting period prior to surgery that can last for several weeks, which is a stressful time.
  • The technology uses a dispersion enhancer that can cause high levels of tumor cell death and necrosis in multiple breast cancer subtypes.

Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTO

Retrieved on: 
Friday, November 12, 2021
Cancer, Therapy, Breast, Poster, Safety, Ottawa Hospital Research Institute, Bristol Myers Squibb, Intensity, Pain, Columbia University Vagelos College of Physicians and Surgeons, STS, Review, Colon, CTOS, Merck Sharp & Dohme Federal Credit Union, NCI, Injection, Cisplatin, Woman, Ontario Institute for Cancer Research, National Cancer Institute, Survival, Patient, Immunosuppression, Diffusion, FDA, Ipilimumab, Sarcoma, Neoplasm, Division, Pembrolizumab, Publication, Fatigue, Hematology, Vinblastine, NCT, LDH, Surgeon, ECOG, Agency, MD, SHAO, Merck, Immune system, Appetite, Cooperative research and development agreement, BMS, Haematoxylin, Eosin, Company, Development, CRADA, Physician, Assistant, Pharmaceutical industry, Vaccine

These results provide further evidence to continue studying this novel therapeutic drug approach."

Key Points: 
  • These results provide further evidence to continue studying this novel therapeutic drug approach."
  • The data presented included results from 19 patients with different metastatic sarcomas treated with INT230-6 either as a monotherapy (n=10), or in combination with a checkpoint inhibitor (n=8) primarily ipilimumab.
  • For sarcoma subjects dosed to >40% of their total tumor burden, approximately 60% of subjects will be alive at 1 year.
  • Intensity Therapeutics, Inc. is a privately held, clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers.